The Study
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials
This study gave some people a new medicine and others a fake pill, then watched what happened. It found that the medicine helped people lose a little weight and didn't make them super sick. But it didn't test it on lots of people or for a long time, so we can't say for sure it will work the same way for everyone.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists tested a new weekly injection called petrelintide in people with extra weight to see if it helps them lose weight and if it’s safe.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 583 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Losing 8–9% of body weight is considered clinically meaningful and similar to top weight-loss drugs, but with fewer severe stomach issues.
- 2People lost up to 8.6% of their body weight (about 17 lbs for a 200-lb person) with the highest dose, while those on placebo lost only 1.7%.
- 3Nausea happened in up to 1 in 3 people, but vomiting and diarrhea were rare.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Diabetes, Obesity & Metabolism
Year
2026
Authors
Minna Brændholt Olsen, Jon Griffin, U. Hövelmann, S. Macura, Berith Fredsted Hagen, Dan Hesse, Tim Heise
Related Content
Claims (6)
In healthy adults with overweight or obesity, taking petrelintide for 16 weeks did not cause measurable changes in blood tests, vital signs, heart rhythm readings, or immune responses.
In adults with overweight or obesity, a weekly injection of petrelintide up to 9.0 mg caused nausea in 16.7% to 33.3% of users, making it the most common stomach-related side effect; vomiting and diarrhea were uncommon, and only one person stopped treatment because of stomach issues.
When injected under the skin, petrelintide remains active in the body for about 10 days, reaches stable blood levels after five doses, and the amount in the blood increases proportionally with the dose between 0.6 and 9.0 milligrams.
In adults with overweight or obesity, a weekly injection of petrelintide for 8 weeks led to an average weight loss of 8.6% after 16 weeks, compared to a 1.7% weight loss with a placebo.
In adults with overweight or obesity, a weekly injection of petrelintide for 16 weeks led to a reduction in waist size of up to 7.6 centimeters, and this change occurred regardless of whether blood sugar levels changed.
In a clinical trial, people who took petrelintide lost 10.7% of their body weight, more than those who took a placebo.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.